RESPECCT: Respiratory syncytial virus and S. pneumoniae Challenge Coinfection Study
You are invited to take part in a challenge study to investigate RSV and SPN co-infection to understand how these two common germs alter the nose environment and impact human health. The study is being run by the Oxford Vaccine Group (as part of the University of Oxford) and the Liverpool School of Tropical Medicine. It is funded by Pfizer Inc.
If you are 18 to 55 years old and in good health, then you may be eligible to take part. We will deliberately expose participants in safe and controlled conditions to either RSV or pneumococcus first through drops in the nose. After this, participants will receive the other infection seven days later. Participants will be asked to self-isolate at home or remain in a medical facility after RSV exposure for up to 10 days to reduce risk to transmission to others. We will provide up to £3130 total reimbursement amount for your time, inconvenience and travel.
Background
This study is looking at two different germs: a bacterium called Streptococcus pneumoniae (‘pneumococcus’, Spn) and a virus called Respiratory syncytial virus (RSV). These germs can cause a variety of symptoms from cold-like illnesses to chest infections or sepsis. When someone is exposed to both, which is very common in winter, it might affect how likely they are to develop infection or how serious their symptoms are. It is important to understand this relationship better so that future studies on treatments or vaccines can be performed.
Study Goals
The study aims to understand how RSV and pneumococcus interact in the nose of healthy adult volunteers. The knowledge generated in this project could be used to help develop new interventions such as anti-virus agents and drugs targeting the host body response.
Study Details
If you are eligible and decide to take part, you would be deliberately expose in safe and controlled conditions to either RSV or pneumococcus first through drops in the nose. After this, participants will receive the other infection seven days later. Participants will be asked to self-isolate at home or remain in a medical facility after RSV exposure for up to 10 days to reduce risk to transmission to others. You would also have samples taken during clinical visits to assess immune response to the germs and you would be required to complete a short online diary for 21 days after exposure. We will provide up to £3130 total reimbursement amount for your time, inconvenience and travel.
The Oxford Vaccine Group, University of Oxford, is based in the Centre for Clinical Vaccinology and Tropical Medicine at the Churchill site, where all study visits / appointments will take place.
Further Information
If you would like to find out more, please read the Participant Information Sheet
THE FOLLOWING SITES ARE CURRENTLY RECRUITING - PLEASE SELECT THE SITE BELOW:
Oxford Vaccine Group, Churchill Hospital site, Oxford: If you are interested in joining the study, please visit Pre-screening Questionnaire where you can access the online screening questions and register your interest.
If you would like any further information regarding the study, please contact us on:
Email: info@ovg.ox.ac.uk Tel: 01865 611400
Kind Regards,
The Oxford Vaccine Group